AR and cancer: RIPTACs are heterobifunctional molecules comprising a ligand that binds to a target protein in cancer cells, such as the AR, and a second ligand that binds to essential effector proteins (EPs) present in all cells whilst both these ligands are connected via a linker (Figure 2) [43, 44].